Clinical Report: Pentraxin-3 as a Systemic Indicator of Pathology
Overview
This study evaluates the role of Pentraxin-3 (PTX3) as a systemic indicator and local inflammatory mediator in thyroid nodules. Elevated plasma PTX3 levels were observed preoperatively in patients with thyroid nodules, with significant declines post-surgery.
Background
Thyroid nodules are prevalent, with a significant portion being benign, yet the mechanisms behind their development remain unclear. Understanding inflammatory mediators like PTX3 could provide insights into the pathology of thyroid diseases.
Data Highlights
Measurement
Preoperative Level (ng/mL)
Postoperative Level (ng/mL)
p-value
PTX3
4.58
3.58
<0.05
Key Findings
Preoperative plasma PTX3 levels were significantly elevated compared to normal reference ranges.
PTX3 levels declined significantly after surgery.
No significant differences in plasma PTX3 levels were found between benign and malignant nodules.
PTX3 expression was significantly higher in malignant tissues compared to healthy thyroid tissues.
Mast cell presence was significantly associated with thyroid cancer.
PTX3's role in inflammation and tissue remodeling in thyroid pathology is highlighted.
Clinical Implications
The findings indicate that PTX3 may serve as a marker of inflammation in thyroid nodular disease.
Conclusion
Increased PTX3 levels were observed in thyroid nodules, but further studies are required to clarify its role.
